The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.
The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.
A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.
A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.
BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.
The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.
A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
A 17-year-old is seeking affordable prescriptions for oral finasteride and minoxidil, considering lying about their age to use costplusdrugs. They are exploring telemedicine options, including Dr.B, to obtain the prescriptions.
The conversation is about obtaining a finasteride prescription through Lemon Aid Health. The user is exploring the process and alternatives for getting the prescription sent to a pharmacy.
A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.
A user's 12 month update on treatment for hair loss, which include oral dutasteride and minoxidil, topical RU88541 and minoxidil, microneedling with hyaluronic acid and FinDuta, experiencing no side effects, positive results and inspiring other users.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.